Sovaprevir

Drug Profile

Sovaprevir

Alternative Names: ACH-0141625; ACH-1625

Latest Information Update: 22 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; Viral nonstructural protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 22 Jul 2015 No recent reports on development identified - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Belgium and Germany (PO)
  • 19 May 2015 Sovaprevir licensed to Janssen Pharmaceuticals worldwide
  • 08 May 2015 Achillion plans the SPARTA doublet regimen trial for Hepatitis C (Combination therapy, Treatment-naive) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top